期刊
FUTURE ONCOLOGY
卷 14, 期 11, 页码 1117-1132出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0636
关键词
afatinib; dacomitinib; EGFR; erlotinib; gefitinib; non-small-cell lung cancer; osimertinib; resistance; treatment sequencing; T790M
类别
资金
- AstraZeneca
- Hoffman LaRoche
- Boehringer Ingelheim
- Pfizer
Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance develops, most commonly due to the T790M mutation. Osimertinib showed clinical activity in the treatment of T790M-positive disease following progression on a first-line TKI, and is approved in this setting. Recently, osimertinib improved efficacy versus first-generation TKIs (erlotinib and gefitinib) in the first-line setting. Multiple factors can influence first-line treatment decisions, including subsequent therapy options, presence of brain metastases and tolerability, all of which should be considered in the long-term treatment plan. Further research into treatment sequencing is also needed, to optimize outcomes in EGFR mutation-positive non-small-cell lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据